Evidence map›Paper›PMID 39250738›Full record

ArticleJournal of the National Cancer Institute2025

The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment.

Michelle C Janelsins, Kathleen Van Dyk, Sheri J Hartman, Thuy T Koll, Christina K Cramer, Glenn J Lesser, Debra L Barton, Karen M Mustian, Lynne I Wagner, Patricia A Ganz and 25 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Treatment-Related Changes in Cerebrospinal Fluid Markers of Oxidative Stress and Neurodegeneration during Therapy for Childhood Acute Lymphoblastic Leukemia.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Trial
  6. Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Self-management of cognitive impairments: a qualitative study of cancer survivor' coping strategies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Michelle C JanelsinsDivision of Supportive Care in Cancer, Department of Surgery, University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, USA.ORCID 0000-0003-2258-7247
Kathleen Van DykDepartment of Psychiatry, David Geffen Scholl of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0003-1500-930X
Sheri J HartmanHerbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, San Diego, CA, USA.
Thuy T KollDivision of Geriatrics, Gerontology and Palliative Medicine, Department of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Christina K CramerDepartment of Radiation Oncology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA.
Glenn J LesserDepartment of Internal Medicine, Section on Hematology and Oncology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA.
Debra L BartonCollege of Nursing, University of Tennessee, Knoxville, Knoxville, TN, USA.
Karen M MustianDivision of Supportive Care in Cancer, Department of Surgery, University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, USA.
Lynne I WagnerDepartment of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Patricia A GanzFielding School of Public Health, University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.
Peter D ColeDepartment of Pediatric Hematology / Oncology, Rutgers Cancer Institute, Princeton, NJ, USA.
Alexis BakosNational Cancer Institute, Bethesda, MD, USA.
James C RootDepartment of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Institute, New York, NY, USA.ORCID 0000-0001-7332-6165
Kristina HardyDivision of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
Allison MagnusonDivision of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, USA.ORCID 0000-0002-0968-8265
Robert J FergusonDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Brenna C McDonaldDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.
Andrew J SaykinDepartment of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.ORCID 0000-0002-1376-8532
Brian D GonzalezMoffitt Cancer Center, Tampa, FL, USA.
Jeffrey S WefelDepartment of Neuro-Oncology, MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-3584-023X
David A MorilakUniversity of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Saurabh DahiyaDivision of Internal Medicine, Stanford University, Palo Alto, CA, USA.
Cobi J HeijnenDepartment of Psychological Sciences, Rice University, Houston, TX, USA.
Yvette P ConleySchool of Nursing, University of Pittsburgh, Pittsburgh, PA, USA.
Alicia K MorgansDepartment of Medicine, Dana Farber Cancer Institute, Boston, MA, USA.
Donald MabbottNeurosciences and Mental Health Program, Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0001-6161-5066
Michelle MonjeDepartment of Pediatric Neuro-Oncology, Stanford University, Palo Alto, CA, USA.
Stephen R RappDepartment of Psychiatry and Behavioral Medicine, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA.
Vinai GondiDepartment of Radiation Oncology, Northwestern Medicine, Chicago, IL, USA.
Catherine BenderSchool of Nursing, University of Pittsburgh, Pittsburgh, PA, USA.
Leanne EmbryUniversity of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Worta McCaskill StevensNational Cancer Institute, Bethesda, MD, USA.
Judith O HopkinsSoutheast Clinical Oncology Research Consortium, Winston-Salem, NC, USA.
Diane St GermainNational Cancer Institute, Bethesda, MD, USA.
Susan G DorseyPain and Translational Symptom Science Department, University of Maryland, Baltimore, Baltimore, MD, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
URCC NCORP Research BaseUG1CA189961 · NCI · UNIVERSITY OF ROCHESTER · PI Michelle C Janelsins, KAREN M. MUSTIAN · 2014 to 2026
$67.7M
Cognitive impairment associated with androgen deprivation therapy for prostate cancerR01CA224672 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MORILAK, DAVID A · 2019 to 2023
$2.0M
Therapy-induced cognitive impairment in a rat model of prostate cancerR01CA285183 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI David A Morilak · 2023 to 2026
$1.6M
Promoting Physical Activity to Improve Cognitive Function in Older Adults Undergoing Hematopoietic Cell Transplantation (HCT)K23AG070311 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KOLL, THUY · 2021 to 2025
$1.1M
HHSNCINCI NIH HHS P30 CA008748NCI NIH HHS R01 CA224672NCI NIH HHS R01 CA285183NCI NIH HHS UG1 CA189961NIA NIH HHS K23 AG070311NIH HHS
6 · The paper itself

Abstract

Cancer-related cognitive impairment is a broad term encompassing subtle cognitive problems to more severe impairment. The severity of this impairment is influenced by host, disease, and treatment factors, and the impairment affects patients before, during, and following cancer treatment. The National Cancer Institute (NCI) Symptom Management and Health-Related Quality of Life Steering Committee (SxQoL SC) convened a clinical trial planning meeting to review the state of the science on cancer-related cognitive impairment and develop phase II/III intervention trials aimed at improving cognitive function in cancer survivors with non-central nervous system disease and longitudinal studies to understand the trajectory of cognitive impairment and contributing factors. Participants included experts in the field of cancer-related cognitive impairment, members of the SxQoL SC, patient advocates, representatives from all 7 NCI Community Oncology Research Program research bases, and the NCI. Presentations focused on the following topics: measurement, lessons learned from pediatric and geriatric oncology, biomarker and mechanism endpoints, longitudinal study designs, and pharmacological and behavioral intervention trials. Panel discussions provided guidance on priority cognitive assessments, considerations for remote assessments, inclusion of relevant biomarkers, and strategies for ensuring broad inclusion criteria. Three clinical trial planning meeting working groups (longitudinal studies as well as pharmacological and behavioral intervention trials) convened for 1 year to discuss and report on top priorities and to design studies. The meeting experts concluded that sufficient data exist to advance phase II/III trials using selected pharmacological and behavioral interventions for the treatment of cancer-related cognitive impairment in the non-central nervous system setting, with recommendations included herein.

Indexed as

Clinical Trials as TopicCognitive DysfunctionNeoplasmsHumansNational Cancer Institute (U.S.)Observational Studies as TopicQuality of LifeResearch DesignUnited States

Identifiers

PMID39250738
PMCPMC11807440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.